

Pro-Inflammatory Cytokines

Subjects: **Oncology**

Contributor: Ru Li , Annie Wen , Jun Lin

Pro-inflammatory cytokines released from tumor cells or stromal cells act in both autocrine and paracrine manners to induce phenotype changes in tumor cells, recruit bone marrow-derived cells, and form an inflammatory milieu, all of which prime a secondary organ's microenvironment for metastatic cell colonization.

pre-metastatic niche

pro-inflammatory cytokines

1. Introduction

Tumor metastasis is the main cause of therapeutic failure and mortality, with few effective treatment options. It has been suggested that the tumor microenvironment plays a prominent role in the formation of metastasis, collaborating with genetic and epigenetic networks in cancer cells ^{[1][2]}. A key step for the formation of tumor metastases is the extravasation of circulating tumor cells into distant organs and their adaption to new environments. Therefore, the reciprocal interactions between the disseminated cancer cells and the microenvironment in distant organs are imperative to successful metastasis. Primary tumor cells orchestrate the metastasis process through secreting a variety of molecules which promote the mobilization and recruitment of various types of cells to the premetastatic sites and alter the expression of matrix proteins and the properties of the extracellular matrix (ECM) in secondary organs. All these events help create the so-called pre-metastatic niche (PMN), suitable for the engraftment of metastasizing tumor cells. The concept of PMN was first proposed by Dr. David Lyden in 2005 ^[3]. Since then, targeting the PMN to prevent metastasis has become a promising strategy for cancer treatment. However, much remains to be revealed about the factors that facilitate the establishment of the implantation site for tumor metastasis.

Priming of the organ-specific premetastatic sites is an important yet incompletely understood step during metastasis formation. Bone marrow-derived cells (BMDCs) and tumor-derived secreted factors are the two crucial components for pre-metastatic niche formation. The main type of BMDCs accumulated in the pre-metastatic niche is myeloid-derived suppressor cells (MDSCs). When infections and tissue injuries occur, the myeloid lineage is promptly expanded, and myeloid leukocytes in the bone marrow perform a protective role in host defense against such stresses and traumas. However, chronic inflammation associated with cancer induces the expression of pro-inflammatory cytokines that drive the differentiation of myeloid cells towards MDSCs. MDSCs are a heterogeneous population of immature myeloid cells including macrophages, granulocytes, neutrophils, and dendritic cells. They accumulate in the circulation of cancer patients and are recruited to peripheral lymphoid organs and tumor sites by growth factors released by cancer cells. Within the tumor microenvironment, MDSC were shown to inhibit the proliferation and activity of killer T cells, promote angiogenesis, and improve tumor cells survival, thereby

promoting tumor invasion and metastasis [4]. Besides the recruited MDSCs, the host stromal environment of the PMN also includes fibroblast, endothelial cells, and ECM.

Tumor-derived secreted factors play important roles in preparing distant organs for pre-metastatic niche formation. Tumor-derived secreted factors include cytokines, chemokines, growth factors, and extracellular vesicles (EV). Cytokines are a diverse family of small proteins secreted by cells, predominantly by helper T cells and macrophages for cell-to-cell communication. Cytokines could act on the cells releasing them (autocrine action), on nearby cells (paracrine action), or on distant cells (endocrine action) and are often produced in a cascade, as one cytokine stimulates its target cells to produce additional cytokines. The major subgroups of cytokines include interleukins, interferons, colony-stimulating factors, chemokines, and tumor necrosis factors. Cytokines exert their effects through binding to cytokine receptors on target cells, which activates a sequence of downstream proteins for the desired responses. It should be noted that the effects of different cytokines are sometimes redundant, with different cytokines eliciting similar responses [5][6]. Cytokines play a key role in tumor progression and metastasis by either directly regulating tumor growth, invasiveness, and metastasis or indirectly affecting stromal cells and immune cells [7]. Accumulating evidence suggests that pro-inflammatory cytokines are pivotal in the formation of the pre-metastatic niche. Tumor cell-derived pro-inflammatory cytokines and chemokines recruit a variety of regulatory and suppressive immune cells into distant sites to prime the local environment. The proliferative and invasive abilities of disseminated cancer cells are enhanced by proinflammatory cytokines from the surrounding microenvironment as paracrine signals. Thus, cancer cells can undergo epithelial-to-mesenchymal transition (EMT) to grow in distant tissues. In this review, we focus on the role of important pro-inflammatory cytokines in the establishment of the PMN and highlight the underlying mechanisms of PMN formation in various organs based on the most recent studies (Figure 1).




Figure 1. Proposed mechanisms by which various pro-inflammatory cytokines promote the formation of the pre-metastatic niche in different organs. Abbreviation: EV: extracellular vesicles; IL-6: interleukin 6; IL-1 β : interleukin-1 β .

1β; SDF-1 α: stromal cell-derived factor 1; IL-8: interleukin 8; VEGF: vascular endothelial growth factor; G-CSF: granulocyte-colony stimulating factor; CCL2: CC-chemokine ligand 2; CXCL1: C-X-C motif ligand 1; MIF: macrophage migration inhibitory factor; TIMP-1: tissue inhibitor of metalloproteinases 1; GM-CSF: granulocyte-macrophage colony-stimulating factor; SAA: serum amyloid A; TGF-β: transforming growth factor beta; FN: fibronectin; ECM: extracellular matrix; STAT3: signal transducer and activator of transcription 3; CAF: cancer associated fibroblast; MDSC: myeloid-derived suppressor cells.

2. Clinical Trials Targeting Pro-Inflammatory Cytokines in Metastatic Cancer

Pro-inflammatory cytokines are key mediators of innate and adaptive immunity at the crossroad of diverse pathways shaping pre-metastatic niches. Nowadays, several agents targeting IL-6, IL-6 receptor, JAKs, or STAT3 have been used in the treatment of myeloma and tested in patients with solid tumors [8][9]. There are two FDA-approved antibodies directly targeting IL-6: siltuximab, a chimeric anti-IL-6 antibody [10], and tocilizumab, a humanized monoclonal antibody against the IL-6 receptor. Various global clinical trials, series, and pilot studies of off-label use of siltuximab and tocilizumab provide strong indications [11] that the anti-IL-6 therapy may be used for the treatment of blood cancers such as multiple myeloma [12] and leukemia [13] and of solid tumors such as prostate cancer [14], breast cancer [15], and ovarian cancer [16]. However, two phase II trials which employed siltuximab as second-line therapy for patients with metastatic prostate cancer showed an increase in plasma IL-6 after treatment and confirmed the poor prognosis associated with elevated IL-6 [10][17]. Two clinical trials, one (NCT04191421) evaluating siltuximab in metastatic pancreatic cancer patients and the other (NCT03135171) evaluating tocilizumab in metastatic HER2-positive breast cancer patients are in progress (Table 1).

Table 1. Registered clinical trials targeting pro-inflammatory cytokines in patients with cancer metastases.

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date
IL-6 pathway								
IL-6								
Siltuximab, anti-IL-6 chimeric monoclonal antibody	NCT00433446	S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients with Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy	Completed	Metastatic Prostate Cancer	Phase 2	62	2007	2011
	NCT00385827	A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male	Terminated	Metastatic Prostate Cancer	Phase 2	106	2017	2021

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date
	Subjects with Metastatic Hormone-Refractory Prostate Cancer (HRPC)		Recruiting	Metastatic Stage IV Pancreatic Cancer	Phase 1 Phase 2	42	2020	2022
	NCT04191421	Siltuximab and Spartalizumab in Patients with Metastatic Pancreatic Cancer						
Tocilizumab, humanized monoclonal antibody against IL-6 receptor	NCT03135171	Trastuzumab and Pertuzumab in Combination with Tocilizumab in Subjects with Metastatic HER2-Positive Breast Cancer Resistant to Trastuzumab	Recruiting	HER2+ Breast Cancer	Phase 1	20	2017	2021
JAK								
Ruxolitinib, JAK1 and JAK2 inhibitor	NCT00638378	Study of Ruxolitinib (INCB018424) Administered Orally to Patients with Androgen-Independent Metastatic Prostate Cancer	Terminated	Prostate Cancer	Phase 2	22	2008	2009
	NCT01594216	Ruxolitinib in Estrogen Receptor-Positive Breast Cancer	Completed	Estrogen Receptor-Positive Invasive Metastatic Breast Cancer	Phase 2	29	2012	2016
	NCT02120417	A Study of Ruxolitinib in Combination with Capecitabine in Subjects with Advanced or Metastatic HER2-Negative Breast Cancer	Terminated	Breast Cancer	Phase 2	149	2014	2017
	NCT02041429	Ruxolitinib W/Preop Chemo for Triple-Negative	Active, not recruiting	Recurrent Breast Cancer Metastatic Breast Cancer	Phase 1 Phase 2	24	2014	2021

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date
	Inflammatory Breast cancer							
	NCT02066532	Ruxolitinib in Combination with Trastuzumab in Metastatic HER2-Positive Breast Cancer	Active, not recruiting	Metastatic Breast Cancer HER-2 Positive Breast Cancer	Phase 1 Phase 2	28	2014	2020
	NCT03012230	Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple-Negative Breast Cancer	Recruiting	Metastatic Malignant Neoplasm in the Bone Stage IV Breast Cancer Triple-Negative Breast Carcinoma	Phase 1	18	2017	2021
	NCT02876302	Study of Ruxolitinib (INCB018424) With Preoperative Chemotherapy for Triple-Negative Inflammatory Breast Cancer	Recruiting	Inflammatory Breast Cancer	Phase 2	64	2017	2024
Itacitinib, JAK1 inhibitor	NCT03670069	Itacitinib in Treating Patients with Refractory Metastatic/Advanced Soft Tissue Sarcomas	Recruiting	Metastatic Leiomyosarcoma Metastatic Synovial Sarcoma	Phase 1	28	2019	2022
STAT								
BBi608, STAT3 inhibitor	NCT03522649	A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients with Metastatic Colorectal Cancer	Recruiting	Previously Treated Metastatic Colorectal Cancer	Phase 3	668	2018	2021
	NCT03647839	Modulation of The Tumor Microenvironment Using Either Vascular Disrupting	Active, not recruiting	Colorectal Cancer Metastatic	Phase 2	90	2018	2022

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date
		Agents or STAT3 Inhibition in Order to Synergize With PD1 Inhibition in Microsatellite-Stable, Refractory Colorectal Cancer Patients						
WP1066, JAK2/STAT3 inhibitor	NCT01904123	STAT3 Inhibitor WP1066 in Treating Patients with Recurrent Malignant Glioma or Progressive Metastatic Melanoma in the Brain	Recruiting	Metastatic Malignant Neoplasm in the Brain Metastatic Melanoma	Phase 1	33	2018	2021
	NCT04334863	AflacST1901: Peds WP1066	Recruiting	Brain Tumor Medulloblastoma BrainMetastases	Phase 1	36	2020	2023
IL-1								
Canakinumab, human anti-IL-1 β monoclonal antibody	NCT03631199	Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy with or without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-Squamous and Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects	Active, not recruiting	Non-Small Cell Lung Cancer	Phase 3	673	2018	2022
	NCT04581343	A Phase 1B Study of Canakinumab, Spartalizumab, Nab-Paclitaxel, and Gemcitabine in Metastatic PC Patients	Recruiting	Metastatic Pancreatic Ductal Adenocarcinoma	Phase 1	10	2020	2022

. Among various JAK inhibitors, ruxolitinib is the most extensively investigated for cancer treatment. Approved by the FDA in 2011 for the treatment of myelofibrosis and post-polycythemia vera, ruxolitinib is a potent and selective oral JAK1 and JAK2 inhibitor. Studies on the safety and effectiveness of ruxolitinib in cancer patients with solid tumors such as breast cancer (NCT01594216, lung cancer (NCT02145637), colorectal cancer (NCT04303403), pancreatic cancer (NCT04303403), and head and neck cancer (NCT03153982) are ongoing. Additional early-phase trials of ruxolitinib have been focused on cancer metastasis, including patients with metastatic prostate cancer and metastatic breast cancer, as listed in [Table 1](#). However, two phase III trials (NCT02119663 and NCT02117479) of ruxolitinib with capecitabine in metastatic pancreatic cancer patients were terminated due to no additional benefit over capecitabine alone [\[18\]](#). The same also occurred with a phase II trial of ruxolitinib with capecitabine in patients with metastatic HER2-positive breast cancer (NCT02120417). Besides ruxolitinib, itacitinib, a JAK1 specific inhibitor, has also been employed in a phase I trial of metastatic soft tissue sarcomas.

The third potential target in the IL-6 signaling pathway is STAT3, with several compounds inhibiting the function or expression of STATs in clinical trials for various solid tumors [\[19\]](#). BBI608, an oral cancer stemness inhibitor that blocks STAT3-mediated transcription of cancer stemness genes in the β -catenin pathway, has reached Phase II

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date	
Anakinra, human interleukin 1 receptor antagonist	NCT00072111	Anakinra in Treating Patients with Metastatic Cancer Expressing the Interleukin-1 Gene	Completed	Metastatic Cancer	Phase 1		2003	2015	2010 [20],
								[21][22]	Currently,
	NCT02090101	Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer	Completed	Metastatic Colorectal Cancer	Phase 2	32	2014	2017	n anti-IL-
	NCT01802970	Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients	Completed	Metastatic Breast Cancer	Phase 1	10	2012	2017	otent IL-treatment of
CCL2									
Carlumab	NCT00992186	Everolimus and Anakinra or Denosumab in Treating Participants with Relapsed or Refractory Advanced Cancers	Active, not recruiting	Advanced Malignant Neoplasm Metastatic Malignant Neoplasm Recurrent Malignant Neoplasm Refractory Malignant Neoplasm	Phase 1	57	2012	2020	umab is anti-IL-1 eases. It ncluding
CSF									
SNDX-6352, CSF receptor inhibitor	NCT03238027	A Study of the Safety and Efficacy of Single-Agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants with Metastatic Castrate-Resistant Prostate Cancer	Completed	Prostate cancer	Phase 2	46	2009	2011	h affinity his trial, l benefit requires a
CSF									
SNDX-6352, CSF receptor inhibitor	NCT03238027	A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in	Active, not recruiting	Solid Tumor Metastatic Tumor	Phase 1	45	2017	2021	fficacy of The trials

knowledge of the mechanisms governing this process. Targeting the molecular interactions that build the PMN has the potential to prevent and eradicate metastases before they manifest. It would be most useful to block the signaling systems that promote the establishment of the PMN right after dissecting a primary tumor, i.e., in the critical post-operative window when no visible metastases are observed but PMN formation is probably ongoing. Compelling evidence implies the rise of pro-inflammatory cytokines and the suppression of the immune function during the peri-operative and post-operative periods [23][24], which all contribute to PMN formation. However, the combination of pro-inflammatory cytokines in the PMN is still under investigation and may vary in different types of cancer or even in individual patients. The advanced ‘omics’ technology could help design more precise and individualized therapeutic approaches in future clinical trials. Admittedly, some clinical trials targeting IL-6 or IL-1 have failed in preventing metastasis. Human solid tumors are more complex than mouse models, and the heterogeneity of cancer cells could be a factor affecting treatment efficacy. Thus, monotherapy to inhibit a single cytokine may not be sufficient to treat advanced tumors. Taking in consideration the pleiotropy and redundancy of pro-inflammatory cytokines, further in vitro and in vivo studies should be designed to determine the joint power of pro-inflammatory cytokines in PMN formation, as well as to analyze their combined targeting in cancer metastasis.

Tested Drug	NCT Number	Title	Status	Conditions	Phases	Enrollment	Start Date	Completion Date	
Patients With Solid Tumors									
SDF-1									
Olaptesed, binding to SDF-1	NCT03168139	Olaptesed (NOX-A12) Alone and in Combination with Pembrolizumab in Colorectal and Pancreatic Cancer Patients	Completed	Metastatic Colorectal Cancer Metastatic Pancreatic Cancer	Phase 1 Phase 2	20	2017	2020	2009, 9,
MIF									
Anti-MIF antibody	NCT01765790	Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors	Completed	Metastatic Adenocarcinoma of the Colon or Rectum	Phase 1	68	2012	2016	1, D.D.; enitors

Therapeutic Target for Cancer. Cells 2020, 9, 561.

- Ozaki, K.; Leonard, W.J. Cytokine and cytokine receptor pleiotropy and redundancy. J. Biol. Chem. 2002, 277, 29355–29358.
- Altan-Bonnet, G.; Mukherjee, R. Cytokine-mediated communication: A quantitative appraisal of immune complexity. Nat. Rev. Immunol. 2019, 19, 205–217.
- Dranoff, G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4, 11–22.
- Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018, 15, 234.
- Sansone, P.; Bromberg, J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 2012, 30, 1005–1014.
- Dorff, T.B.; Goldman, B.; Pinski, J.K.; Mack, P.C.; Lara, P.N., Jr.; Van Veldhuizen, P.J., Jr.; Quinn, D.I.; Vogelzang, N.J.; Thompson, I.M., Jr.; Hussain, M.H. Clinical and correlative results of SWOG S0354: A phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin. Cancer Res. 2010, 16, 3028–3034.
- Kampan, N.C.; Xiang, S.D.; McNally, O.M.; Stephens, A.N.; Quinn, M.A.; Plebanski, M. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities. Curr. Med. Chem. 2018, 25, 4785–4806.
- Iftikhar, A.; Hassan, H.; Iftikhar, N.; Mushtaq, A.; Sohail, A.; Rosko, N.; Chakraborty, R.; Razzaq, F.; Sandeep, S.; Valent, J.N.; et al. Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies 2019, 8, 34.

13. Riegler, L.L.; Jones, G.P.; Lee, D.W. Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. *Ther. Clin. Risk Manag.* 2019, 15, 323–335.
14. Culig, Z.; Puhr, M. Interleukin-6 and prostate cancer: Current developments and unsolved questions. *Mol. Cell. Endocrinol.* 2018, 462, 25–30.
15. Masjedi, A.; Hashemi, V.; Hojjat-Farsangi, M.; Ghalamfarsa, G.; Azizi, G.; Yousefi, M.; Jadidi-Niaragh, F. The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. *Biomed. Pharmacother.* 2018, 108, 1415–1424.
16. Angevin, E.; Tabernero, J.; Elez, E.; Cohen, S.J.; Bahleda, R.; van Laethem, J.L.; Ottensmeier, C.; Lopez-Martin, J.A.; Clive, S.; Joly, F.; et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. *Clin. Cancer Res.* 2014, 20, 2192–2204.
17. Fizazi, K.; De Bono, J.S.; Flechon, A.; Heidenreich, A.; Voog, E.; Davis, N.B.; Qi, M.; Bandekar, R.; Vermeulen, J.T.; Cornfeld, M.; et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. *Eur. J. Cancer* 2012, 48, 85–93.
18. Giaccone, G.; Sanborn, R.E.; Waqar, S.N.; Martinez-Marti, A.; Ponce, S.; Zhen, H.; Kennealey, G.; Erickson-Viitanen, S.; Schaefer, E. A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation. *Clin. Lung Cancer* 2018, 19, e567–e574.
19. Zou, S.; Tong, Q.; Liu, B.; Huang, W.; Tian, Y.; Fu, X. Targeting STAT3 in Cancer Immunotherapy. *Mol. Cancer* 2020, 19, 145.
20. Horiguchi, A.; Asano, T.; Kuroda, K.; Sato, A.; Asakuma, J.; Ito, K.; Hayakawa, M.; Sumitomo, M.; Asano, T. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. *Br. J. Cancer* 2010, 102, 1592–1599.
21. Dinarello, C.A.; Simon, A.; van der Meer, J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. *Nat. Rev. Drug Discov.* 2012, 11, 633–652.
22. Molgora, M.; Supino, D.; Mantovani, A.; Garlanda, C. Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8. *Immunol. Rev.* 2018, 281, 233–247.
23. Li, R.; Huang, Y.; Lin, J. Distinct effects of general anesthetics on lung metastasis mediated by IL-6/JAK/STAT3 pathway in mouse models. *Nat. Commun.* 2020, 11, 642.

24. Hiller, J.G.; Perry, N.J.; Poulogiannis, G.; Riedel, B.; Sloan, E.K. Perioperative events influence cancer recurrence risk after surgery. *Nat. Rev. Clin. Oncol.* 2018, 15, 205–218.
-

Retrieved from <https://encyclopedia.pub/entry/history/show/34749>